n a surprise ruling, a federal judge on Thursday sided with Amgen in a patent dispute — effectively banning Sanofi and Regeneron Pharmaceuticals from selling a competing cholesterol drug.

In 30 days, Sanofi and Regeneron will no longer be able to sell their treatment, Praluent, in the US, leaving Amgen’s Repatha as the sole drug of its type on the market.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.